Department of Trauma and Orthopaedics, Royal National Orthopaedic Hospital, Stanmore, United Kingdom.
J Arthroplasty. 2024 Jul;39(7):1811-1819. doi: 10.1016/j.arth.2024.01.028. Epub 2024 Jan 19.
Patients presenting with periprosthetic osteolysis or fracture between ipsilateral hip and knee arthroplasties are challenging to treat successfully. Long-stem implants, osteopenic bones, and patient comorbidities all represent considerable surgical challenges. Poor results of fracture fixation in this group, coupled with the desire to retain well-performing implants and minimize soft-tissue trauma led to the developmentof the custom cement-over megaprostheses (CCOM). The aims of the study were to evaluate implant survivals, complications, and patient outcomes in those undergoing CCOM within our institution.
A retrospective analysis of patients undergoing CCOM between 2002 and 2022 was performed. We studied 34 cases, 33 patients, one patient underwent staged bilateral surgery with 26 women and 8 men.
trauma (16), failure of implants /aseptic loosening (9), or joint pathology. The mean Charlson comorbidity index was 3.5 (range, 0 to 8). All patients were followed up (mean 75 months [range, 9 to 170]) at 6 weeks, 6 months, 1 year, and annually thereafter. The VAS, EuroQol-5D-3L and MSTS scores were collected at 1 year.
Implant survival defined by the primary outcome (all-cause revision of the implant at any time point) at 12 months of 97% (32 of 33). In surviving patients, implant survival was 90% (18 of 20) and all 7 survived at 5 and 10 years, respectively. Implant survival including those in the primary outcome group and those free of infection at 12 months was 84.8% (28 of 33) and in surviving patients, implant survival was 70% (14 of 20) and 7 out of 7 at 5 and 10 years, respectively.
The CCOM technique demonstrates good implant survivorships and satisfactory patient-reported outcomes in complex, often frail patients who have compromised bone stock. This series confirms the technique as an established alternative to total femoral replacement in these cases.
同侧髋关节和膝关节置换术后出现假体周围骨溶解或骨折的患者治疗效果具有挑战性。长柄植入物、骨质疏松骨骼和患者合并症都给手术带来了相当大的挑战。该组患者骨折固定效果不佳,同时希望保留性能良好的植入物并尽量减少软组织损伤,这导致了定制骨水泥覆盖型 megaprostheses(CCOM)的发展。本研究的目的是评估我们机构内接受 CCOM 的患者的植入物存活率、并发症和患者结局。
对 2002 年至 2022 年间接受 CCOM 的患者进行回顾性分析。我们研究了 34 例病例,33 名患者,1 名患者接受分期双侧手术,其中 26 名女性,8 名男性。
创伤(16 例)、植入物失败/无菌性松动(9 例)或关节病变。平均 Charlson 合并症指数为 3.5(范围 0 至 8)。所有患者均接受随访(平均随访 75 个月[范围 9 至 170 个月]),随访时间分别为术后 6 周、6 个月、1 年和此后每年 1 次。在 1 年时收集 VAS、EuroQol-5D-3L 和 MSTS 评分。
以任何时间点(任何原因的植入物翻修)为主要结局的植入物存活率在 12 个月时为 97%(33 例中的 32 例)。在存活患者中,植入物存活率为 90%(20 例中的 18 例),分别有 7 例在 5 年和 10 年时存活。包括主要结局组和无感染的 12 个月时的植入物存活率为 84.8%(33 例中的 28 例),在存活患者中,植入物存活率为 70%(20 例中的 14 例),分别有 7 例在 5 年和 10 年时存活。
在骨骼条件较差的复杂、体弱患者中,CCOM 技术具有良好的植入物存活率和满意的患者报告结局。本系列研究证实,该技术是这些病例中全股骨置换的一种替代方法。